Class / Patent application number | Description | Number of patent applications / Date published |
514286000 | Two of the cyclos share at least three ring members (i.e., bridged) | 15 |
20080275075 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative - The invention provides a medicine comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative of the formula (I): | 11-06-2008 |
20090076059 | DEUTERIUM-ENRICHED DIANICLINE - The present application describes deuterium-enriched dianicline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090088448 | Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders - Provided is a method of treating neurodegenerative disorders comprising administering to a subject in need thereof a compound of formula I: | 04-02-2009 |
20090318490 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION - Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states. | 12-24-2009 |
20100069423 | Use of Chk2 Kinase Inhibitors for Cancer Treatment - Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof. | 03-18-2010 |
20100069424 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY - The present invention concerns the compounds of formula | 03-18-2010 |
20100093779 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 04-15-2010 |
20110152306 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES - The present application relates to indole and indoline derivatives of formula (I) | 06-23-2011 |
20130190344 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 07-25-2013 |
20130197022 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY - The present invention concerns the compounds of formula | 08-01-2013 |
20140018383 | MYELOID DIFFERENTIATION INDUCING AGENTS - Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders. | 01-16-2014 |
20140171461 | Nitrogen Containing Morphinan Derivatives and the Use Thereof - The application is directed to compounds of Formula I-A | 06-19-2014 |
20150119417 | METHODS FOR TREATING VISCERAL FAT CONDITIONS - Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion. | 04-30-2015 |
20160115178 | SOLID FORMS OF A MACROCYCLIC KINASE INHIBITOR - This invention relates to crystalline solvates of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans. | 04-28-2016 |
20220135592 | SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS - Disclosed herein are novel substituted macrocycle compounds according to Formula I, or pharmaceutically acceptable salts, solvates, or enantiomers thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions. | 05-05-2022 |